Insilico Medicine Receives FDA Fast Track Designation for ISM6331, the AI-driven Pan-TEAD Inhibitor, in Advanced Mesothelioma Written by PR Newswire Enable JavaScript and cookies to continueRead more http://www.prnasia.com/story/archive/5013684_CN13684_0